
25 Nov 2024
Polarean Imaging Initiation - On the cusp of hyperbolic growth
Despite initial FDA approval and grant of the requisite reimbursement codes, investor confidence in Polarean is low, as reflected in the current share price. However, revenue growth is already accelerating and is set to go hyperbolic as Polarean's Xenon MRI platform meets a large unmet clinical need that cannot be satisfied by other methods. Crossing the bridge to profitability will require additional funding but there is a cash runway through 1Q26. Polarean has potential upside many times its current market capitalisation, we calculate, based on observable deal metrics and our NPV analysis, while the valuation is so low, it could attract take-over interest, we believe.

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Polarean Imaging Initiation - On the cusp of hyperbolic growth
Polarean Imaging Plc (POLX:LON) | 1.1 0 0.0% | Mkt Cap: 13.3m
- Published:
25 Nov 2024 -
Author:
Colin Smith -
Pages:
38 -
Despite initial FDA approval and grant of the requisite reimbursement codes, investor confidence in Polarean is low, as reflected in the current share price. However, revenue growth is already accelerating and is set to go hyperbolic as Polarean's Xenon MRI platform meets a large unmet clinical need that cannot be satisfied by other methods. Crossing the bridge to profitability will require additional funding but there is a cash runway through 1Q26. Polarean has potential upside many times its current market capitalisation, we calculate, based on observable deal metrics and our NPV analysis, while the valuation is so low, it could attract take-over interest, we believe.